The European Medicines Agency's PRIME scheme to accelerate the development of promising drugs that address unmet medical needs has enrolled 19 products in its first year, showing considerable overlap with FDA breakthrough therapy designees but also key differences.
This is a preview of subscription content, log in via an institution to check access.
PowerPoint slides
Rights and permissions
About this article
Cite this article
Mullard, A. PRIME time at the EMA. Nat Rev Drug Discov 16, 226–228 (2017). https://doi.org/10.1038/nrd.2017.57
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrd.2017.57
- Springer Nature Limited
This article is cited by
-
Postmarketing all-case surveillance trends and contribution to safety measures of drugs approved in Japan: a cross-sectional survey in 1999–2019
International Journal of Clinical Pharmacy (2023)